| 8.405 -0.295 (-3.39%) | 05-22 15:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.07 | 1-year : | 20.79 |
| Resists | First : | 12.91 | Second : | 17.79 |
| Pivot price | 7.85  |
|||
| Supports | First : | 5 | Second : | 4.16 |
| MAs | MA(5) : | 8.76 |
MA(20) : | 7.76 |
| MA(100) : | 12.2  |
MA(250) : | 19.3 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 29.3 |
D(3) : | 29.8 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 100.8 | Low : | 0.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HCWB ] has closed below upper band by 38.9%. Bollinger Bands are 28.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.22 - 9.27 | 9.27 - 9.3 |
| Low: | 8.43 - 8.49 | 8.49 - 8.54 |
| Close: | 8.62 - 8.71 | 8.71 - 8.78 |
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Tue, 20 May 2025
Insider Buying: Hing Wong Acquires Additional Shares of HCW Biologics Inc (HCWB) - GuruFocus
Fri, 16 May 2025
HCW Biologics Inc Reports Q1 2025 Earnings: Revenue at $5,065, Net Loss Reduced to $2.2 Million - GuruFocus
Thu, 15 May 2025
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results - GlobeNewswire
Thu, 15 May 2025
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results - Stock Titan
Tue, 13 May 2025
HCW Biologics Announces Positive Results of Studies of - GlobeNewswire
Tue, 13 May 2025
HCW Biologics Raises Fresh Capital: $5M Follow-On Offering Includes Attractive Warrant Package - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 400520 (%) |
| Held by Institutions | 39.7 (%) |
| Shares Short | 10 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.83e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 129.6 % |
| Return on Equity (ttm) | -62.8 % |
| Qtrly Rev. Growth | 2.57e+006 % |
| Gross Profit (p.s.) | -81.63 |
| Sales Per Share | -1043.46 |
| EBITDA (p.s.) | 1.11558e+006 |
| Qtrly Earnings Growth | -30.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -1.19 |
| Dividend | 0 |
| Forward Dividend | 6920 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|